1
|
Gutman D, Lidzbarsky G, Milman S, Gao T, Sin-Chan P, Gonzaga‐Jauregui C, Deelen J, Shuldiner AR, Barzilai N, Atzmon G. Similar burden of pathogenic coding variants in exceptionally long-lived individuals and individuals without exceptional longevity. Aging Cell 2020; 19:e13216. [PMID: 32860726 PMCID: PMC7576295 DOI: 10.1111/acel.13216] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 06/22/2020] [Accepted: 07/12/2020] [Indexed: 12/13/2022] Open
Abstract
Centenarians (exceptionally long‐lived individuals—ELLI) are a unique segment of the population, exhibiting long human lifespan and healthspan, despite generally practicing similar lifestyle habits as their peers. We tested disease‐associated mutation burden in ELLI genomes by determining the burden of pathogenic variants reported in the ClinVar and HGMD databases using data from whole exome sequencing (WES) conducted in a cohort of ELLI, their offspring, and control individuals without antecedents of familial longevity (n = 1879), all descendent from the founder population of Ashkenazi Jews. The burden of pathogenic variants did not differ between the three groups. Additional analyses of variants subtypes and variant effect predictor (VEP) biotype frequencies did not reveal a decrease of pathogenic or loss‐of‐function (LoF) variants in ELLI and offspring compared to the control group. Case–control pathogenic variants enrichment analyses conducted in ELLI and controls also did not identify significant differences in any of the variants between the groups and polygenic risk scores failed to provide a predictive model. Interestingly, cancer and Alzheimer's disease‐associated variants were significantly depleted in ELLI compared to controls, suggesting slower accumulation of mutation. That said, polygenic risk score analysis failed to find any predictive variants among the functional variants tested. The high similarity in the burden of pathogenic variation between ELLI and individuals without familial longevity supports the notion that extension of lifespan and healthspan in ELLI is not a consequence of pathogenic variant depletion but rather a result of other genomic, epigenomic, or potentially nongenomic properties.
Collapse
Affiliation(s)
- Danielle Gutman
- Faculty of Natural Sciences University of Haifa Haifa Israel
| | | | - Sofiya Milman
- Department of Medicine Albert Einstein College of Medicine Bronx New York USA
| | - Tina Gao
- Department of Medicine Albert Einstein College of Medicine Bronx New York USA
| | | | | | - Joris Deelen
- Max Planck Institute for Biology of Ageing Cologne Germany
- Molecular Epidemiology Department of Biochemical Data Sciences Leiden University Medical Center Leiden The Netherlands
| | | | - Nir Barzilai
- Department of Medicine Albert Einstein College of Medicine Bronx New York USA
- Genetic, Institute for Aging Research and the Diabetes Research Center Albert Einstein College of Medicine Bronx New York USA
| | - Gil Atzmon
- Faculty of Natural Sciences University of Haifa Haifa Israel
- Department of Medicine Albert Einstein College of Medicine Bronx New York USA
- Genetic, Institute for Aging Research and the Diabetes Research Center Albert Einstein College of Medicine Bronx New York USA
| | | |
Collapse
|
2
|
Empirical design of a variant quality control pipeline for whole genome sequencing data using replicate discordance. Sci Rep 2019; 9:16156. [PMID: 31695094 PMCID: PMC6834861 DOI: 10.1038/s41598-019-52614-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2019] [Accepted: 10/18/2019] [Indexed: 12/29/2022] Open
Abstract
The success of next-generation sequencing depends on the accuracy of variant calls. Few objective protocols exist for QC following variant calling from whole genome sequencing (WGS) data. After applying QC filtering based on Genome Analysis Tool Kit (GATK) best practices, we used genotype discordance of eight samples that were sequenced twice each to evaluate the proportion of potentially inaccurate variant calls. We designed a QC pipeline involving hard filters to improve replicate genotype concordance, which indicates improved accuracy of genotype calls. Our pipeline analyzes the efficacy of each filtering step. We initially applied this strategy to well-characterized variants from the ClinVar database, and subsequently to the full WGS dataset. The genome-wide biallelic pipeline removed 82.11% of discordant and 14.89% of concordant genotypes, and improved the concordance rate from 98.53% to 99.69%. The variant-level read depth filter most improved the genome-wide biallelic concordance rate. We also adapted this pipeline for triallelic sites, given the increasing proportion of multiallelic sites as sample sizes increase. For triallelic sites containing only SNVs, the concordance rate improved from 97.68% to 99.80%. Our QC pipeline removes many potentially false positive calls that pass in GATK, and may inform future WGS studies prior to variant effect analysis.
Collapse
|
3
|
Sebastiani P, Gurinovich A, Nygaard M, Sasaki T, Sweigart B, Bae H, Andersen SL, Villa F, Atzmon G, Christensen K, Arai Y, Barzilai N, Puca A, Christiansen L, Hirose N, Perls TT. APOE Alleles and Extreme Human Longevity. J Gerontol A Biol Sci Med Sci 2019; 74:44-51. [PMID: 30060062 PMCID: PMC6298189 DOI: 10.1093/gerona/gly174] [Citation(s) in RCA: 82] [Impact Index Per Article: 16.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Indexed: 12/11/2022] Open
Abstract
We assembled a collection of 28,297 participants from seven studies of longevity and healthy aging comprising New England Centenarian, Long Life Family, Longevity Gene Population, Southern Italian Centenarian, Japanese Centenarian, the Danish Longevity, and the Health and Retirement Studies to investigate the association between the APOE alleles ε2ε3 and ε4 and extreme human longevity and age at death. By using three different genetic models and two definitions of extreme longevity based on either a threshold model or age at death, we show that ε4 is associated with a substantially decreased odds for extreme longevity, and increased risk for death that persists even beyond ages reached by less than 1% of the population. We also show that carrying the ε2ε2 or ε2ε3 genotype is associated with significantly increased odds to reach extreme longevity, with decreased risk for death compared with carrying the genotype ε3ε3 but with only a modest reduction in risk for death beyond an age reached by less than 1% of the population.
Collapse
Affiliation(s)
- Paola Sebastiani
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Anastasia Gurinovich
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
- Bioinformatics Program, Boston University, Massachusetts
| | - Marianne Nygaard
- The Danish Aging Research Center and The Danish Twin Registry, Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Takashi Sasaki
- Center for Supercentenarian Research, Keio University, Tokyo, Japan
| | - Benjamin Sweigart
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts
| | - Harold Bae
- College of Public Health and Human Sciences, Oregon State University, Corvallis, Oregon
| | - Stacy L Andersen
- Geriatric Section, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts
| | - Francesco Villa
- Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy
| | - Gil Atzmon
- Faculty of Natural Science, University of Haifa, Israel
- Department of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York
| | - Kaare Christensen
- The Danish Aging Research Center and The Danish Twin Registry, Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Yasumichi Arai
- Center for Supercentenarian Research, Keio University, Tokyo, Japan
| | - Nir Barzilai
- Department of Medicine and Genetics, Albert Einstein College of Medicine, Bronx, New York
| | - Annibale Puca
- Cardiovascular Research Unit, IRCCS MultiMedica, Milan, Italy
- Department of Medicine and Surgery, University of Salerno, Baronissi, Italy
| | - Lene Christiansen
- The Danish Aging Research Center and The Danish Twin Registry, Epidemiology, Biostatistics and Biodemography, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Nobuyoshi Hirose
- Center for Supercentenarian Research, Keio University, Tokyo, Japan
| | - Thomas T Perls
- Geriatric Section, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts
| |
Collapse
|
4
|
Freudenberg-Hua Y, Li W, Davies P. The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. Front Med (Lausanne) 2018; 5:108. [PMID: 29740579 PMCID: PMC5928202 DOI: 10.3389/fmed.2018.00108] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2018] [Accepted: 04/03/2018] [Indexed: 12/12/2022] Open
Abstract
Alzheimer's disease (AD) is the most common type of dementia, which has a substantial genetic component. AD affects predominantly older people. Accordingly, the prevalence of dementia has been rising as the population ages. To date, there are no effective interventions that can cure or halt the progression of AD. The only available treatments are the management of certain symptoms and consequences of dementia. The current state-of-the-art medical care for AD comprises three simple principles: prevent the preventable, achieve early diagnosis, and manage the manageable symptoms. This review provides a summary of the current state of knowledge of risk factors for AD, biological diagnostic testing, and prospects for treatment. Special emphasis is given to recent advances in genetics of AD and the way genomic data may support prevention, early intervention, and development of effective pharmacological treatments. Mutations in the APP, PSEN1, and PSEN2 genes cause early onset Alzheimer's disease (EOAD) that follows a Mendelian inheritance pattern. For late onset Alzheimer's disease (LOAD), APOE4 was identified as a major risk allele more than two decades ago. Population-based genome-wide association studies of late onset AD have now additionally identified common variants at roughly 30 genetic loci. Furthermore, rare variants (allele frequency <1%) that influence the risk for LOAD have been identified in several genes. These genetic advances have broadened our insights into the biological underpinnings of AD. Moreover, the known genetic risk variants could be used to identify presymptomatic individuals at risk for AD and support diagnostic assessment of symptomatic subjects. Genetic knowledge may also facilitate precision medicine. The goal of precision medicine is to use biological knowledge and other health information to predict individual disease risk, understand disease etiology, identify disease subcategories, improve diagnosis, and provide personalized treatment strategies. We discuss the potential role of genetics in advancing precision medicine for AD along with its ethical challenges. We outline strategies to implement genomics into translational clinical research that will not only improve accuracy of dementia diagnosis, thus enabling more personalized treatment strategies, but may also speed up the discovery of novel drugs and interventions.
Collapse
Affiliation(s)
- Yun Freudenberg-Hua
- Litwin-Zucker Center for the study of Alzheimer’s Disease, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, United States
- Division of Geriatric Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, United States
| | - Wentian Li
- Robert S Boas Center for Genomics and Human Genetics, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, United States
| | - Peter Davies
- Litwin-Zucker Center for the study of Alzheimer’s Disease, The Feinstein Institute for Medical Research, Northwell Health, Manhasset, NY, United States
| |
Collapse
|